Cefixime
drugOn this page
Also known as Anhydrous cefiximeCefiximaCefixime anhydrousCefixime hydrateCefixime trihydrateCephoralCitropenCL 284,635CL-284635CefspanFK 027FK-027FR 17027FR-17027OrokenSupraxSID85148376CefiximeÊCefiximeÂ
Summary
Cefixime (CHEMBL1541) is an approved small-molecule antibacterial drug (ATC J01DD08); indicated across 14 conditions including otitis media and urinary tract infection.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: J01DD08
- Indications: 14 conditions
- Clinical trials: 22
- Chemistry: 453.5 Da · C16H15N5O7S2
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1541 |
| Name | Cefixime |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 5362065 |
| ChEBI | CHEBI:472657 |
| ATC | J01DD08 |
| Molecular formula | C16H15N5O7S2 |
| Molecular weight | 453.5 |
| InChIKey | OKBVVJOGVLARMR-QSWIMTSFSA-N |
SMILES: C=CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\OCC(=O)O)/C3=CSC(=N3)N)SC1)C(=O)O
IUPAC name: (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(carboxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
ChEBI definition: A third-generation cephalosporin antibiotic bearing vinyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It is used in the treatment of gonorrhoea, tonsilitis, pharyngitis, bronchitis, and urinary tract infections.
Pharmacological roles (ChEBI): antibacterial drug, drug allergen.
Also known as: Anhydrous cefixime, Cefixima, Cefixime, Cefixime anhydrous, Cefixime hydrate, Cefixime trihydrate, Cephoral, Citropen, CL 284,635, CL-284635, Cefspan, FK 027
Patent coverage: 7,477 distinct patent families (27,787 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Lethal(3)malignant brain tumor-like protein 1, Apoptotic protease-activating factor 1, NAD-dependent protein deacylase sirtuin-5, mitochondrial, 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1, ATP-binding cassette sub-family C member 2.
Bioactivity
ChEMBL activities: 2 potent at pChembl ≥ 5 of 6 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| PLCG1 | 5.92 | IC50 | 1212 | nM | CHEMBL_ACT_14158100 |
| APAF1 | 5.04 | EC50 | 9080 | nM | CHEMBL_ACT_6457442 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
14 indications (9 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| otitis media | 4 | MONDO:0005441 | EFO:0004992 |
| urinary tract infection | 4 | MONDO:0100338 | EFO:0003103 |
| tonsillitis | 4 | MONDO:0001039 | HP:0011110 |
| bacterial infectious disease | 4 | MONDO:0005113 | EFO:0000771 |
| bronchitis | 4 | MONDO:0003781 | HP:0012388 |
| pharyngitis | 4 | MONDO:0002258 | MONDO:0002258 |
| gonorrhea | 4 | MONDO:0004277 | DOID:7551 |
| chronic bronchitis | 4 | MONDO:0005607 | EFO:0006505 |
| syphilis | 3 | MONDO:0005976 | EFO:0007504 |
| HIV infectious disease | 3 | MONDO:0005109 | EFO:0000764 |
| neoplasm | 1 | MONDO:0005070 | EFO:0000616 |
| osteomyelitis | 0 | MONDO:0005246 | EFO:0003102 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 22.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1 | 8 |
| PHASE4 | 4 |
| PHASE3 | 4 |
| PHASE2 | 4 |
| PHASE1/PHASE2 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02224040 | PHASE4 | UNKNOWN | Typhoid Fever: Combined vs. Single Antibiotic Therapy |
| NCT04349826 | PHASE4 | COMPLETED | The Azithromycin and Cefixime Treatment of Typhoid in South Asia Trial (ACT-South Asia Trial) |
| NCT06090565 | PHASE4 | COMPLETED | Cefixime Plus Doxycycline Compared to Ceftriaxone Plus Azithromycin for Treatment of Gonorrhoea |
| NCT06907316 | PHASE4 | TERMINATED | Cefixime Versus Benzathine Penicillin G in Treatment of Early Syphilis |
| NCT04958122 | PHASE3 | RECRUITING | Cefixime Clinical Trial |
| NCT01072136 | PHASE3 | TERMINATED | Empiric Therapy of Mucopurulent Cervicitis (MPC) |
| NCT02021006 | PHASE3 | UNKNOWN | Antibiotic Prophylaxis and Renal Damage In Congenital Abnormalities of the Kidney and Urinary Tract |
| NCT03969758 | PHASE3 | UNKNOWN | Ciprofloxacin Plus Metronidazole Vs Cefixime Plus Metronidazole Therapy for the Treatment of Liver Abscess |
| NCT06406114 | PHASE2 | RECRUITING | Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing |
| NCT01595529 | PHASE2 | COMPLETED | The SCOUT Study: Short Course Therapy for Urinary Tract Infections in Children |
| NCT03660488 | PHASE2 | COMPLETED | Cefixime for Alternative Syphilis Treatment |
| NCT03752112 | PHASE1/PHASE2 | UNKNOWN | Trial Evaluating the Clinical Efficacy of Cefixime for Treatment of Early Syphilis in Non-pregnant Women |
| NCT05294588 | PHASE2 | COMPLETED | Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae |
| NCT00004216 | PHASE1 | COMPLETED | VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Therapy |
| NCT00093353 | PHASE1 | COMPLETED | N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma |
| NCT00186979 | PHASE1 | COMPLETED | Study of ZD1839 Combined With Irinotecan and Vincristine in Pediatric Patients With Refractory Solid Tumors |
| NCT00786669 | PHASE1 | COMPLETED | A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors |
| NCT01949363 | PHASE1 | COMPLETED | The Pharmacokinetics of Extended Duration High-dose Cefixime for the Decreased Susceptibility of Neisseria Gonorrhoeae: A Phase I Pilot Study |
| NCT02596503 | PHASE1 | COMPLETED | A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors |
| NCT02708992 | PHASE1 | COMPLETED | Cefixime / Azithromycin pK Study |
| NCT03840811 | PHASE1 | COMPLETED | Experimental Human Infection With Neisseria Gonorrhoeae |
| NCT04982861 | Not specified | COMPLETED | Bioequivalence Study of Cefixime Trihydrate Dry Syrup in Indonesia Healthy Volunteers |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).